← All Allovir, INC filings

Allovir, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

ALVR
Allovir, INC
DEF: Kalaris Therapeutics 2026 Annual Meeting Proxy Statement
Kalaris Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on June 3, 2026.
ALVR
Allovir, INC
DEFA14A: Kalaris Therapeutics Schedules 2025 Annual Stockholders Meeting to Elect Directors and Ratify Auditor
Kalaris Therapeutics, Inc. has announced its Annual Meeting of Stockholders for August 12, 2025, to vote on the election of two Class II directors and the ratification of Deloitte & Touche LLP as its independent registered public accounting firm.
ALVR
Allovir, INC
DEF: Kalaris Therapeutics Sets 2025 Annual Meeting Agenda, Details Post-Merger Governance and Executive Compensation
Kalaris Therapeutics, Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on August 12, 2025, where shareholders will vote on director elections and auditor ratification, following its recent merger with Legacy Kalaris Tx, Inc.
ALVR
Allovir, INC
DEF 14A: AlloVir Seeks Stockholder Approval for Reverse Stock Split to Maintain Nasdaq Listing
AlloVir is asking shareholders to approve a reverse stock split to increase its share price and maintain its listing on the Nasdaq Capital Market.
ALVR
Allovir, INC
DEFA14A: AlloVir, Inc. Sets Date for 2024 Annual Meeting, Outlines Proposals for Stockholder Vote
AlloVir, Inc. announces its 2024 Annual Meeting of Stockholders to be held virtually on June 6, 2024, with voting open until June 5, 2024.
ALVR
Allovir, INC
DEF 14A: AlloVir, Inc. Announces 2024 Annual Meeting of Stockholders
AlloVir, Inc. is set to hold its 2024 Annual Meeting of Stockholders virtually on June 6, 2024, to elect directors and ratify the appointment of its independent accounting firm.